SeaStar Medical Holding Corporation (ICU) Earnings Call Transcript & Summary
August 12, 2026
Earnings Call Speaker Segments
Jackie Cossmon
executiveThanks, Josh. It's a pleasure to have everyone with us this afternoon for SeaStar Medical's conference call covering our second quarter 2026 financial results. I'm Jackie Cossmon, and I work with Wheelhouse Life Science Advisors. Here with me today from SeaStar Medical are Eric Schlorff, our Chief Executive Officer; Tim Varacek, Senior Vice President of Commercial and Business Operations; Dr. Kevin Chung, Chief Medical Officer; and Michael Messinger, Chief Financial Officer. A quick reminder for those listening: management's remarks on this call will contain forward-looking statements as defined under Federal Securities laws. Such statements carry risks and uncertainties that might lead actual results to differ materially from anything anticipated. To see a list and description of those risks and uncertainties, please look at SeaStar Medical's filings with the Securities and Exchange Commission. Also, what's said on this conference call is accurate only as of the moment of the live broadcast, August 12, 2026. Except where the law requires it, SeaStar Medical assumes no obligation to revise or update any statements in light of events or circumstances. At this point, I'll hand things over to Eric. Eric?
Eric Schlorff
executiveThanks, Jackie, and I appreciate everyone being here with us today. We're really happy with how things went during this quarter. The extent to which we've penetrated the pediatric AKI market, together with ongoing robust growth in QUELIMMUNE revenue, signals strong things ahead for the opportunity we see in the adult AKI market, which is 50 times bigger than the pediatric market here in the U.S. As patient care teams successfully treat pediatric AKI using QUELIMMUNE therapy, the close-knit pediatric critical care community gains more clinical confidence, and we think that will only boost the future potential launch of this therapy in the adult AKI market. Tim is going to say more about our plans for continuing to drive adoption of QUELIMMUNE in pediatric AKI, and he'll also talk about how we're strategically preparing for a possible launch of this therapy in adult AKI. Kevin will walk through where we stand in the NEUTRALIZE-AKI pivotal clinical trial as well as our regulatory strategy for the adult AKI indication. Before handing things to Tim, for anyone who's new to SeaStar Medical's story, I want to make something clear: the same foundational therapy found in QUELIMMUNE, which is called the Selective Cytopheretic Device, or SCD, is the very therapeutic device we're studying in our pivotal trial for the adult AKI indication. The adult version is just a bigger device, built to handle larger blood volumes; I'd also like to stress that our SCD therapy is first in class. It's the sole immunomodulatory therapy that targets and neutralizes hyperactive leukocytes and monocytes, along with the immune cells chiefly responsible for triggering the cytokine storm that shuts down organs and takes the lives of far too many patients with AKI requiring renal replacement therapy. Because of the unique mechanism behind our SCD therapy and the substantial value of finding a possible solution to this ongoing unmet need, I'd point out that we expect our current pharmaceutical-like gross margins to persist for QUELIMMUNE and to carry over to our adult therapies if they're approved. On top of that, we believe the FDA appreciates how important it is to bring innovative treatment advancements to critically ill patients with AKI. The FDA cleared QUELIMMUNE for pediatric AKI under Humanitarian Device Exemption and additionally granted us Breakthrough Device Designation for the SCD therapy for adult patients with AKI on continuous renal replacement therapy, which ought to support a more collaborative and rapid approval process. We've also been given Breakthrough Device Designations for our other pipeline indications, such as systemic inflammation from cardiac surgery and chronic inflammation in end-stage renal disease, among others. I'm giving this context today to restate our firm belief that the opportunity before us is significant; we stay keenly focused on hitting our near-term goals and recognize how important it is to drive new customer adoption for QUELIMMUNE and to enroll patients in our NEUTRALIZE-AKI trial. At the same time, we aren't losing sight of our long-term opportunities and everything SeaStar Medical can accomplish for all our stakeholders. With that, I'll hand it over to Tim. Tim?
Tim Varacek
executiveAppreciate it, Eric, and thank you all for being here with us today. Our work to make QUELIMMUNE a key therapy for critically ill pediatric patients dealing with AKI and sepsis is advancing really well. Right now, 20 out of the 50 top children's hospitals across the U.S. have bought and utilized our QUELIMMUNE therapy. Keep in mind, our target for 2026 is to grow the hospital count to 25 by year-end, starting from 10 at the outset. That means we've already doubled our customer base during this year, and we're making solid headway toward that objective. As Eric mentioned, adoption of QUELIMMUNE therapy is resonating widely among the pediatric critical care community. I'll take you through the details. When we held our Q1 call, we discussed how much attention QUELIMMUNE drew at the AKI and CRRT conference in San Diego. Beyond that enthusiasm, a few weeks ago we both sponsored and participated in the KidneyBee Summit for this year. This annual gathering brings together a deeply specialized, interdisciplinary group — nurses, advanced practice providers, nephrologists, and critical care physicians drawn from across the nation. What makes it so valuable is its focus on the systemic breakdowns that leave pediatric kidney failure insufficiently recognized. And as recently as yesterday, we assembled top experts in treating pediatric AKI for a presentation during a SeaStar Medical educational webinar. Our webinar was called "Rethinking Pediatric Sepsis-Associated AKI: What Clinicians Should Know About QUELIMMUNE." Practicing pediatric nephrologists, critical care physicians, advanced practice providers, and nurses came together with us to deepen their understanding of pediatric sepsis-associated AKI, to see through case reviews how QUELIMMUNE therapy gets used, and to figure out ways of handling QUELIMMUNE adoption within hospital settings. Attendance at both events was robust, and the pediatric community used the opportunity to obtain answers regarding important operational matters, to engage with substantial material drawn from the newest scientific and clinical data in sepsis-associated pediatric AKI, and to discover how that knowledge could be put to work so they can employ our QUELIMMUNE therapy at the hospitals where they practice. We've noted previously that this is an extremely uncommon patient group facing substantial unmet medical needs. As the sole and first treatment option for pediatric patients dealing with AKI alongside sepsis, QUELIMMUNE is fostering fresh approaches within the pediatric AKI field. Switching now to our sales goals and upcoming prospects within this ultra-rare pediatric sector. For the second quarter, QUELIMMUNE net revenues came in at $615,000, which marks a robust 82% rise compared to the same period a year ago. We brought in $1.1 million in net revenue over the six-month period, and the momentum is still solid as we work toward hitting $2 million in net revenue by 2026. Put simply, the pace at which QUELIMMUNE is being adopted has us quite optimistic, and our attention stays on bringing in additional customers as fast as we can. We hold high hopes for reaching more patients by getting our QUELIMMUNE therapy into additional pediatric hospitals. When we look at 2027 and beyond, we believe our total addressable market can expand beyond the top 50 pediatric medical centers. Back in June, we shared that the Centers for Medicare & Medicaid Services, or CMS, granted ICD-10-PCS codes for our SCD therapy, which lets hospitals bill efficiently for QUELIMMUNE when it's used to treat sepsis-associated pediatric AKI. It's our belief that every future potential indication coming from our SCD therapy will rely on that same PCS code. That new ICD-10-PCS code takes effect on October 1st of this year. From an administrative standpoint, this matters a great deal, since it takes away yet another possible hurdle to QUELIMMUNE being adopted. On top of that, the 50-patient SAVE registry the FDA required us to complete, in order to further assess the safety profile of our QUELIMMUNE therapy, is now finished. Our preliminary report has been turned in, and right now we're preparing the final version for the FDA to review. The results we saw in the first 21 patients were published in Pediatric Nephrology, a peer-reviewed journal with a strong reputation, and that publication by itself has driven continued interest in adopting QUELIMMUNE. In closing, the outlook for our QUELIMMUNE therapy appears encouraging as we continue expanding within the pediatric market and at the same time carry out pre-commercialization efforts focused on the adult AKI population, which is believed to be 50 times bigger than the U.S. population of pediatric AKI tied to sepsis. Thank you for listening. I'll now turn things over to Kevin Chung, our Chief Medical Officer. Kevin?
Kevin Chung
executiveAppreciate that, Tim, and I also want to thank each of you for joining the call. Tim's excitement regarding the expanding footprint we have within the pediatric critical care field is something I share. Hearing about how nephrology and critical care teams are taking up QUELIMMUNE therapy and recognizing that it genuinely represents a first-in-class option is deeply gratifying. For these children, the time left may be measured in days, sometimes hours, and numerous accounts have reached us of initial QUELIMMUNE use producing outcomes that saved lives; those accounts are genuinely extraordinary, and they keep affirming and underscoring the importance of extending this therapy to a wider group of patients. Let me be clear: in our view, QUELIMMUNE for the pediatric AKI indication represents merely the opening entry among a wide array of indications for our SCD therapy. Based on what we know, there is no other pharmaceutical therapy or medical device currently on the market capable of identifying, targeting, and neutralizing the particular immune cells responsible for hyperinflammation; consequently, the distinctive immunomodulatory mechanism of SCD puts us in a position to potentially transform how serious inflammatory conditions are treated across many areas. That covers not only AKI, but cardiorenal syndrome, systemic inflammation stemming from cardiac surgery, chronic inflammation associated with end-stage renal disease, and further states of pathologic immune activation in which dysregulated cytokine release pushes organs toward failure and patients toward death. That leads me into talking about the work we're doing to extend our SCD therapy to critically ill adults suffering from AKI who require CRRT. Right now we are running the NEUTRALIZE-AKI trial, and we intend to submit a modular pre-market approval, or PMA, with the FDA as a way to potentially accelerate the overall approval pathway for this significant indication. Through the modular PMA, the FDA can review and potentially offer comments on individual portions of our application before all modules are submitted, with the final module being the NEUTRALIZE-AKI clinical trial results. I should add as well that we have received Breakthrough Device Designation for this indication, which ought to help speed up regulatory review. As a reminder, the NEUTRALIZE-AKI pivotal trial is a randomized control trial intended to evaluate the SCD therapy in critically ill adults with AKI requiring CRRT. Mortality or dialysis dependence at 90 days, taken as a composite, forms the primary endpoint. Enrollment now stands at 223 out of the 339 patients we anticipate in total, and we have ramped up recruitment at our sites to hasten the pace of enrollment going forward. Two more clinical sites were recently brought on board, and they have already enrolled patients. Another four sites should begin screening patients in the near future, and a minimum of eight further sites have made a commitment to take part in the trial. Our sites are highly driven and screen patients without pause. Once a potentially eligible patient is identified, our sites are generally able to obtain consent and get that patient enrolled in our trial. That reflects really well on the people running these trials at each site, along with the highly capable research teams, because they sit with families and discuss these matters so thoughtfully at the moment a patient is fighting for their life in intensive care. Let me be clear that our focus right now, and going forward, is enrolling the right category of patients. Being that selective about who gets included is essential when the goal is demonstrating that the therapy actually works, and when we want to avoid the same pitfalls that tripped up prior studies in AKI and sepsis. One of the requirements we use to enrich the population is a C-reactive protein — CRP — measurement greater than 3.5 mg/dL. If someone's CRP comes in at or below that 3.5 mg/dL threshold, they don't get enrolled. Why do we do that? CRP is a highly sensitive marker for inflammation, so a patient whose CRP is low probably won't see any benefit from our therapeutic device. Many patients of that sort ended up enrolled in older interventional trials for sepsis or AKI that targeted inflammation, and ultimately those studies did not succeed. Beyond CRP, we rely on carefully designed exclusion criteria to filter out individuals whose existing medical conditions could obscure the true treatment effect, as well as those who might die regardless of whether the SCD works. That's the same rigorous approach we applied in our pediatric trials, and it's the right way to build a study that can demonstrate therapeutic benefit. One key point to keep in mind is that the way a clinical trial population gets put together is intentionally narrower than what you encounter in everyday practice. Out in the commercial world, what we're observing is that doctors have already begun prescribing QUELIMMUNE to a much wider set of pediatric patients than just the ones who took part in our studies — and that includes kids dealing with complicated comorbidities who never would have qualified under our trial criteria. Seeing that broader real-world uptake tells us physicians have real faith in this therapy, and it also signals that the pool of patients we could potentially reach is larger than the enrollment figures from our trials alone would imply. Meanwhile, NEUTRALIZE-AKI continues to move forward in a meaningful way, and our belief in how the trial is structured and how the sites are carrying it out has never been stronger. Like we talked about, enrolling the correct patients matters more than speeding up enrollment, and our sites are meeting that bar. We still think enrollment will wrap up near the end of the year or during the first quarter of 2027, but the timing for our PMA submission in late 2027 hasn't shifted. Because we have Breakthrough Device Designation for this indication, the FDA will be ready to act fast once we file. If the SCD therapy wins PMA approval for adults with AKI on CRRT, we could commercialize it with ICD-10-PCS codes already available, which would make hospital adoption much easier. Beyond that, because of the footing we're building among pediatric critical care physicians with QUELIMMUNE, we think that will help drive faster uptake by kidney and critical care specialists treating adults with AKI. We care deeply about our capacity to better the outcomes, and possibly rescue the lives, of these extremely sick patients, and we're eager to share updates on how we're doing. On that note, I'll pass things along to Michael Messinger, our CFO. Mike?
Michael Messinger
executiveThanks, Kevin, and I appreciate all of you being on the call today. I'll give a quick rundown of the financial results we posted for the second quarter of 2026. Just so you know, our Form 10-Q is going to be submitted to the SEC sometime in the next 24 hours, and it will contain a more detailed look at how the company performed financially during the three months that ended June 30, 2026. That 10-Q can be accessed at sec.gov, or you can find it on our website, seastarmedical.com. For the second quarter, net revenue came in at $615,000, which shows demand for QUELIMMUNE has been rising. That works out to an 82% jump from net revenue of roughly $338,000 in the second quarter of 2025, and it marks an acceleration from the 69% growth rate we saw in the first quarter. In the second quarter of 2026, we kept our gross profit percentage above 90%, which matches what we've reported for the previous four quarters. Now let's look at operating expenses. During the second quarter of 2026, operating expenses totaled $4.4 million, versus $2.1 million in the second quarter of 2025. The rise in our research and development expenses was driven mainly by more clinical sites and higher patient enrollment relative to the same period in 2025. Our general administrative expenses also went up compared to the second quarter of 2025, largely because of higher compensation costs, legal and professional fees, and some SEC-related expenses. As we mentioned on our first quarter call, we anticipated that our research and development costs would rise on a sequential quarterly basis as we added more clinical sites and pushed our recruitment efforts. We did record an increase in the roughly mid-single-digit range over the first quarter, and we expect that same pattern to continue through the rest of 2026 as we work toward hitting our enrollment goals. For the second quarter of 2026, net loss was about $3.7 million, or $0.91 per share, with weighted average shares outstanding of roughly 4.1 million shares. That's compared to a net loss of approximately $2 million, or $1.77 per share, in the second quarter of 2025, when weighted average shares outstanding were about 1.1 million. As of June 30, 2026, cash on our balance sheet stood at approximately $7 million, down from $12 million at December 31, 2025. With that, I'll hand things back to Eric.
Eric Schlorff
executiveThanks, Mike. What we aimed to do in today's session was walk you through what we accomplished during the second quarter, while also making clear just how tightly concentrated we are on the value drivers that matter most, near term as well as over the long haul, for everyone with a stake in our company. At SeaStar Medical, our team is small yet deeply committed, and even so, we hold the conviction that we are changing what's possible for children and, down the road, possibly for adults who frequently confront organ failure or death absent novel therapies capable of modulating the cytokine storm in acute kidney injury. Our aim is to establish a more elevated benchmark for treating every patient who endures the trauma of AKI. The opportunities awaiting SeaStar Medical strike us as substantial, and we are eager to provide updates on our progress going forward. With that said, I'll turn it over to the operator so we can begin the question-and-answer portion. Operator?
Dave Bautz
analystGood afternoon, everyone, and thanks for taking my questions. To start, could you share what the monthly enrollment rate currently looks like for NEUTRALIZE-AKI, and are you noticing any kind of pickup in enrollment at the newer sites that handle high volumes? And finally, how confident are you, in quantifiable terms, about reaching those 339 patients either by the end of the year or in the first quarter of 2027?
Eric Schlorff
executiveYeah, thanks for asking. I'll take the second part of that. Essentially, what we've communicated to the market is that our timeline centers on year-end or into Q1. Of course, that hinges on Kevin and his team adding more sites and so forth when it comes to enrollment. That said, I'm quite proud of the work Kevin and his team are doing to get those sites up and running at that pace; but thinking about this, David, before he perhaps speaks to enrollment, we continue to believe we remain very much on track, at the end of the day, for a submission of the final PMA module at the close of 2027, which clearly doesn't really have an effect on the timeline. But perhaps, Kevin, you could say a bit about enrollment across the different sites.
Kevin Chung
executiveOkay, thanks Eric. Over the past several months, we've been averaging roughly 8 to 10 to 12 patients during each of those months. That pace is somewhat slower than I'd prefer. But I must stress, the right patients are what we need. When I say right patients, I'm talking about those whose disease is modifiable. What good does it do to complete enrollment if, out of a rush to simply hit our target number, we sign up a group of patients who aren't the right ones? That approach would be deeply flawed. For me, the priority is enrolling the correct patients, which maximizes our odds of success. That's the first point. Second, as we covered in the report, in our update, we're extremely busy at the moment activating—in the midst of activating—many sites. As I mentioned, four are extremely close to activation, with only a few remaining signatures and so forth, and we're prepared to activate them; very soon we'll be getting some reinforcements, with another four sites ready to go. Already trained. SIVs, site initiation visits, already done. Those sites are ready. There are eight more sites, and half of them reached out to us because they wanted to join the trial. They've committed. Whether we'll manage to activate all eight is still uncertain, but we'll attempt to get as many activated as we can, since that will bring us to 15 to 20 subjects per month, a pace I'd be happier with. Once again, though, the emphasis stays on the right patients. The right patients are essential. Getting that right is necessary if we're to have any shot at a positive trial.
Dave Bautz
analystAll right, excellent. Given that enrollment should wrap up before this year ends, in early 2027, and you're aiming to file the PMA by the close of 2027, could you take us through the key steps involved in the PMA that still need to be completed — for instance, following enrollment or following database lock — before the submission can actually go out in full?
Eric Schlorff
executiveYes. What you're asking is, what are a few of the Well, after we lock the database, clearly at that point we'll release top-line results. After locking, we're able to run analyses, and so on; from there, it's basically a matter of filing the clinical portion, essentially, since every one of the other earlier sections will already have been turned in by then. That's genuinely the objective, so that when the FDA takes its time, they're able to concentrate purely on the clinical sections rather than needing to review items such as device and description, and so forth. That's genuinely the approach.
Dave Bautz
analystAll right, that makes sense. One final item—regarding the revenue growth, could you break out how much came from customers you already had compared with the hospitals newly brought on board in the quarter?
Eric Schlorff
executiveSure. Appreciate it. Tim, would you like to take that question?
Tim Varacek
executiveAbsolutely. What drove those sales was a mix of fresh hospital networks plus ones we already had. Among the sites already working with us, the rate at which they buy again is really strong, and clearly, when new sites join, they're eager to get the product on their shelves right away so they can begin treating patients. So really, every customer out there contributed to that result.
Dave Bautz
analystAll right, that's excellent. Thanks for letting us ask a few things.
Eric Schlorff
executiveAppreciate it, David.
Tim Varacek
executiveThank you.
Anthony Vendetti
analystHi there, and thanks. Could you walk us through the milestones that fall between finishing enrollment and the eventual PMA submission? I believe you said the preliminary one was submitted, correct?
Eric Schlorff
executiveNo — what we're submitting are preliminary reports.
Anthony Vendetti
analystYeah.
Eric Schlorff
executiveSo we're submitting
Anthony Vendetti
analystRight, so the discussion is around the PMA, isn't that correct? That's for adults.
Eric Schlorff
executiveCorrect.
Anthony Vendetti
analystYeah.
Eric Schlorff
executiveYeah. So when you look at what we're doing at this moment, obviously it's a PMA built in a modular fashion. You've got different sections in there — one covering the device, another addressing sterilization, plus all kinds of technical items that are part of the whole thing. But the real objective, Anthony, once you get past those parts, is getting those sections in front of the FDA already, with the conversations about them already having happened with the agency. So at the end of the day, what you're essentially waiting on is data lock — after that you're able to present top line and run the analysis, and from there all you're really doing is handing over the clinical section.
Anthony Vendetti
analystAlright. So the certain sections have already been submitted by you, is that right?
Eric Schlorff
executiveNo, that process is still underway.
Anthony Vendetti
analystAnd yet—
Eric Schlorff
executiveYes, that's something we're working through right now. Yes.
Anthony Vendetti
analystUnderstood. So at this moment you've got roughly 20 pediatric hospitals, is that right?
Eric Schlorff
executiveThat's right.
Anthony Vendetti
analystIs there some kind of procedure, or what steps must be taken, to ensure they aren't merely, you know, a hospital that happens to use this? How do you transform them into more substantial repeat buyers? Or is it simply that patients need to arrive and are already committed, leaving nothing further to be done with those specific hospitals?
Eric Schlorff
executiveYes, perhaps, Tim, you might tackle that, and then Kevin, should you wish to provide any further remarks in addition; what we bring to these hospital systems is truly a multidisciplinary strategy.
Anthony Vendetti
analystAll right.
Tim Varacek
executiveYes, that's definitely true. To help you understand, imagine a hospital joined us as of today; they've officially brought QUELIMMUNE on board. A whole series of steps had to happen around IRB approval, qualifying as a vendor, and everything else required to essentially become a customer of that hospital system. After that, a patient turns up in the emergency department, is transferred into the ICU, and QUELIMMUNE ends up being something they think of first. Then our clinical team steps in. They'll assist with getting that initial patient set up so that everything goes without a hitch; as for what follows, there's plenty of work ahead. Each hospital system is big. They employ many different people, they run different shifts, and you truly need an ongoing educational effort directed at that hospital system that never stops. That's because staff turnover happens, just as in any other industry, and our aim is to keep growing not only how broad but also how deep our reach is across all existing customers plus the new ones we'll bring on, so that QUELIMMUNE stays front of mind for patient care teams. Our belief is that although QUELIMMUNE is an extremely effective treatment, if someone hasn't heard of it and a patient arrives when none of your champions are present, they might not recognize that QUELIMMUNE could be used for that patient. It takes continuous effort on the commercial side and the clinical side to make sure we truly embed the brand within these hospital systems, and that they grasp its clinical value, so they spot patients as they arrive and can opt to use QUELIMMUNE therapy as a choice when it's sitting there and it's accessible.
Anthony Vendetti
analystAll right. I just want to get this straight — clearly, being in the hospital is only the beginning. You also need to make certain that every qualified healthcare professional who might use it, first, understands what it offers and understands how to operate it, and that you remain involved, since, as you mentioned, whenever new physicians, nurses, or others like that arrive, you want to be sure they know about the therapy and about how QUELIMMUNE is applied. Is that right?
Tim Varacek
executiveAbsolutely. Yes.
Anthony Vendetti
analystAll right.
Kevin Chung
executiveAllow me to provide additional context from the clinical standpoint.
Anthony Vendetti
analystSure.
Kevin Chung
executiveWe held a webinar yesterday, and we're going to make it accessible shortly, so anyone who couldn't attend or ran into technical problems can still call in. In that conversation, one thing was already evident, but it became even clearer to me: there's a substantial gap between newly activated locations that have the device and established locations that have it. With new locations, whenever a technology is novel, even when it saves lives, the medical community tends to be quite skeptical, and that skepticism is widespread, so they need to witness it working; as a result, it generally gets used as a rescue therapy. What I mean is that at new locations, it's deployed as a final option. Frequently, a number of other experimental treatments that aren't even approved get applied before SCD. So that describes new locations; that's the way they approach it; that's held true for virtually every location brought online, because when a therapy is new, that outcome is inevitable. I must say, I want to stress that even among those patients who had failed other treatments, we're discussing a 70% survival rate in that group, and I want to stress that this is extraordinary. Yesterday, we began to somewhat observe a change, particularly among the mature centers, the mature locations that have now been performing this for more than a year. At those locations, everyone has already been educated, everyone has already witnessed what I refer to as the index case, the aha moment, the case that won them over and, in their thinking, prompted them to say, "Oh my gosh, we need to do this." This is happening, and mental clinical adoption is happening almost universally throughout our mature locations. At this very moment, as we speak, those clinicians are reviewing their ICU to determine who might benefit from the therapy; it's no longer a rescue therapy now. They aren't holding off until the bitter end. They're beginning these patients earlier, and we're observing even stronger outcomes, which is truly extraordinary. So that was what I took away from the webinar. Once again, we'll make it accessible shortly. Hopefully, you can watch it and confirm what I've said. Thanks.
Anthony Vendetti
analystNo, that helps, Kevin. Yeah. We realize the priority, as it ought to be, is the pediatric market and, with this trial enrollment, now adult AKI, and you're sitting at 223 up to 339 patients, and we understand adult AKI is 50 times bigger than the pediatric market. There are additional markets your Selective Cytopheretic Device can address, be that acute respiratory distress, hepatorenal syndrome, cardiorenal syndrome and, naturally, sepsis. I realize you want to remain focused, as I said you ought to, but behind the scenes, could you provide some insight into what sort of work is being done on these other indications?
Eric Schlorff
executiveYeah.
Kevin Chung
executiveYeah. Okay.
Eric Schlorff
executiveI can tackle that one.
Kevin Chung
executiveAll right.
Eric Schlorff
executiveYes. Naturally, we look at every other possible use case that, from where we sit, clearly there is quite an extensive list of items that would certainly make up what we'd hope to accomplish. Yet clearly, as an organization, we must keep our attention on particular priorities, and those have truly centered on QUELIMMUNE for pediatric AKI and adult AKI along with NEUTRALIZE-AKI. Clearly, we have the NEUTRALIZE-CRS study, which in fact receives funding from NIH; and I'd say we hold multiple conversations with multiple groups, examining anything ranging from non-dilutive to strategic talks, business development, across all such matters, so we can genuinely push this forward. The additional indications that we think sit within our pipeline, though clearly, some of those will simply require time before they mature, and we will just need to observe how they turn out.
Kevin Chung
executiveLet me jump in very briefly here. For NEUTRALIZE-AKI, everyone should keep in mind that from the outset we flag individuals who have ARDS when they enroll and who have sepsis when they enroll, and assignment happens through a method known as block randomization. The effect of that is to make sure subjects get spread evenly across the ARDS group, the sepsis group, and the group with sepsis plus ARDS together; as a result, we can definitely speak to those particular populations that also have AKI, naturally.
Anthony Vendetti
analystNo, that was quite useful. I appreciate it. Thanks to Eric, Kevin, and everybody. All right, I'll get back in line. Thanks.
Jackie Cossmon
analystThank you, Josh, and I want to thank each of you for being with us today for SeaStar Medical's conference call on the second quarter financial results. Should you have any questions, feel free to reach out to us at ir@seastarmed.com, or you can check out our site at www.seastarmedical.com. Thanks, and farewell.
Operator
operatorAppreciate it — that brings the call to a close. Thanks for being with us. You’re free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete SeaStar Medical Holding Corporation transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to SeaStar Medical Holding Corporation earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in SeaStar Medical Holding Corporation or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.